Skip to main content

Special Situations III: Medicines for Children

  • Chapter
  • First Online:
Clinical Pharmacology: Current Topics and Case Studies
  • 2613 Accesses

Abstract

The majority of drugs have never been evaluated for use in children. Developmental differences between adults and children of different ages affect pharmacokinetics and pharmacodynamics and the safety profile of drugs. Use of drugs without paediatric information carries risks such as inappropriate dosing, lack of efficacy, and different adverse events as in adults. Paediatric drug studies have been hampered by ethical and legal restrictions, methodological challenges and economical restraints. Recently, regulatory initiatives to stimulate paediatric drug development have been implemented in the USA and EU. The EU Paediatric Regulation ‘Better Medicines for Children’ requires paediatric development according to a Paediatric Investigation Plan (PIP) for all new drugs and on-patent drugs when applying for an authorisation extension. Paediatric development is rewarded with a 6-month patent extension. PIPs are reviewed and amended by a Paediatric Committee at the European Medicines Agency. Certain collateral measures are included that are intended to improve information and transparency and to stimulate research into paediatric medicines. Key points to consider for a PIP are the definition of relevant paediatric indications(s), development of age-appropriate formulation(s), juvenile animal studies, paediatric PK and PD studies, clinical efficacy and safety studies, and the possibility of extrapolation from adults. A case study on a PIP is provided.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Wilson JT (1999) An update on the therapeutic orphan. Pediatrics 104:585–590

    CAS  PubMed  Google Scholar 

  2. Turner S, Gill A, Nunn T, Hewitt B, Choonara I (1996) Use of ‘off-label’ and unlicensed drugs in paediatric intensive care unit. Lancet 347:549–550

    Article  CAS  PubMed  Google Scholar 

  3. Conroy S, Mclntyre J, Choonara I (1999) Unlicensed and off label drug use in the neonate. Arch Dis Child Fetal Neonatal Ed 80:F142–F145

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Conroy S, Choonara I, Impicciatore P, Mohn A, Arnell H, Rane A, Knoeppel C, Seyberth H, Pandolfmi C, Raffaelli MP, Rocchi F, Bonati M, Jong G, de Hoog M, van den Anker J (2000) on behalf of the European Network for Drug Investigation in Children. Survey of unlicensed and off label drug use in paediatric wards in European countries. BMJ 320:79–82

    Google Scholar 

  5. T’ Jong GW, Eland IA, Sturkenboom MC, van den Anker JN, Strieker BH (2002) Unlicensed and off-label prescription of drugs to children: a population based cohort study. BMJ 324:1313–1314

    Article  Google Scholar 

  6. Lindell-Osuagwu L, Korhonen MJ, Saano S, Helin-Tanninen M, Naaranlahti T, Kokki H (2009) Off-label and unlicensed drug prescribing in three paediatric wards in Finland and review of the international literature. J Clin Pharm Ther 34:277–287

    Article  CAS  PubMed  Google Scholar 

  7. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE (2003) Developmental pharmacology: drug disposition, action, and therapy in infants and children. N Engl J Med 349:1157–1167

    Article  CAS  PubMed  Google Scholar 

  8. Johnson TN (2005) Modelling approaches to dose estimation in children. Br J Clin Pharmacol 59(6):663–669

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Sutherland JM (1959) Fatal cardiovascular collapse of infants receiving large amounts of chloramphenicol. AMA J Dis Child 97:761–767

    CAS  PubMed  Google Scholar 

  10. Horen B, Montastruc J, Lapeyre-Mestre M (2002) Adverse drug reactions and off-label drug use in paediatric outpatients. Br J Clin Pharmacol 54:665–670

    Article  PubMed  PubMed Central  Google Scholar 

  11. Turner S, Nunn AJ, Fielding K, Choonara I (1999) Adverse drug reactions to unlicensed and off-label drugs on paediatric wards: a prospective study. Acta Paediatr 88:965–968

    Article  CAS  PubMed  Google Scholar 

  12. European Parliament (2001) Directive 2001/20/EC of the European Parliament and Council of 4 April 2001. Off J Eur Commun L121:34–44

    Google Scholar 

  13. Kauffman RE (2000) Clinical trials in children: problems and pitfalls. Paediatr Drugs 2:411–418

    Article  CAS  PubMed  Google Scholar 

  14. US Food and Drug Administration (2007) Pediatric research equity act (PREA) and best pharmaceuticals for children act (BPCA). http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM049870.pdf. Accessed 24 Apr 2010

  15. Food and Drug Administration Safety and Innovation Act (2012) US Public Law No. 112-144, 126 Stat. 993

    Google Scholar 

  16. National Research Council (2012) Safe and effective medicines for children: pediatric studies conducted under the best pharmaceuticals for children act and the pediatric research equity act. National Academies Press, Washington, DC

    Google Scholar 

  17. Regulation (EC) No. 1901/2006 and 1902/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use (2006) Paediatric regulation. Official J Eur Union 18: L378/1

    Google Scholar 

  18. European Medicines Agency, PDCO report to the European commission 2014. http://ec.europa.eu/health/files/paediatrics/2014_annual-report.pdf. Accessed 09 2015

  19. European Commission (2013) Better medicines for children – from concept to reality. General report on experience acquired as a result of the application of the regulation on medicinal products for paediatric use. http://ec.europa.eu/health/files/paediatrics/2013_com443/paediatric_report-com(2013)443_en.pdf. Accessed 09 2015

  20. Mukattash T, Hawwa AF, Trew K, McElnay JC (2011) Healthcare professional experiences and attitudes on unlicensed/off-label paediatric prescribing and paediatric clinical trials. Eur J Clin Pharmacol 67:449–461

    Article  PubMed  Google Scholar 

  21. European Medicines Agency: needs for paediatric medicines. http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000096.jsp&mid=WC0b01ac0580925b1e#section1. Accessed 09 2015

  22. European Medicines Agency: report on the survey of all paediatric uses of medicinal products in Europe. www.ema.europa.eu/docs/en_GB/document_library/Report/2011/01/WC500101006.pdf. Accessed 09 2015

  23. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) (2000) Clinical investigation of medicinal products in the pediatric population, E11

    Google Scholar 

  24. European Medicines Agency, Committee for Medicinal Products for Human Use (2006) Reflection paper: formulations of choice for the Paediatric population, EMEA/CHMP/PEG/194810/2005

    Google Scholar 

  25. Chappell K, Newman C (2004) Potential tenfold drug overdoses on a neonatal unit. Arch Dis Child Fetal Neonatal Ed 89:F483–F484

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. European Medicines Agency, Committee for Human Medicinal Products (2008) Guideline on the need for non-clinical testing in Juvenile Animals on Human Pharmaceuticals for Paediatric Indications, EMEA/CHMP/SWP/169215/2005

    Google Scholar 

  27. De Schaepdrivjer LM, Bailey GP (2009) Preclinical juvenile toxicity assessments and study designs. In: Mulberg AE, Silber SA, van den Anker JN (eds) Paediatric drug development, concepts and applications. Wiley-Blackwell, Hoboken

    Google Scholar 

  28. European Medicines Agency, Committee for Medicinal Products for Human Use (2006) Guideline on the role of pharmacokinetics in the development of medicinal products in the paediatric population. EMEA/CHMP/EWP/147013/2004

    Google Scholar 

  29. Manolis E, Pons G (2009) Proposals for model based paediatric medicinal development within the current EU regulatory framework. Br J Clin Pharmacol 68:493–501

    Article  PubMed  PubMed Central  Google Scholar 

  30. Bjorkman S (2004) Prediction of drug disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modelling: theophylline and midazolam as model drugs. Br J Clin Pharmacol 59(6):691–704

    Article  Google Scholar 

  31. Anderson BJ, Allegaert K, Holford NH (2006) Population clinical pharmacology of children: general principles. Eur J Pediatr 165:741–746

    Article  PubMed  Google Scholar 

  32. European Medicines Agency (2013) Concept paper on extrapolation of efficacy and safety in medicine development. www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/04/WC500142358.pdf. Accessed 09 2015

  33. European Medicines Agency (2015) Decision on rivaroxaban PIP modification. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/pips/EMEA-000430-PIP01-08-M07/pip_000339.jsp&mid=WC0b01ac058001d129. Accessed 09 2015

  34. Kreutz R (2012) Pharmacodynamic and pharmacokinetic basics of rivaroxaban. Fundam Clin Pharmacol 26:27–32

    Article  CAS  PubMed  Google Scholar 

  35. Investigators EINSTEIN (2010) Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 363:2499–2510

    Article  Google Scholar 

  36. Willmann S, Becker C, Burghaus R, Coboeken K, Edginton A, Lippert J, Siegmund HU, Thelen K, Mück W (2014) Development of a paediatric population-based model of the pharmacokinetics of rivaroxaban. Clin Pharmacokinet 53(1):89–102

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Attard C, Monagle P, Kubitza D, Ignjatovic V (2012) The in vitro anticoagulant effect of rivaroxaban in children. Thromb Res 130:804–807

    Article  CAS  PubMed  Google Scholar 

  38. Attard C, Monagle P, Kubitza D, Ignjatovic V (2014) The in-vitro anticoagulant effect of rivaroxaban in neonates. Blood Coagul Fibrinolysis 25:237–240

    Article  CAS  PubMed  Google Scholar 

  39. U.S. National Institutes of Health, Clinical trials registry: studies of rivaroxaban in children. https://clinicaltrials.gov/ct2/results?term=rivaroxaban+and+children&Search=Search. Accessed 09 2015

  40. Young G (2015) Development of a rivaroxaban dosing regimen for treatment of VTE in children aged 12 to 18 years. J Thromb Haemost 13 Suppl: (abstract)

    Google Scholar 

  41. European Medicines Agency (2015) Decision on apixaban PIP modification. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/pips/EMEA-000183-PIP01-08-M03/pip_000193.jsp&mid=WC0b01ac058001d129. Accessed 09 2015

  42. Akl EA, Ramly EP, Kahale LA, Yosuico VE, Barba M, Sperati F, Cook D, Schünemann H (2014) Anticoagulation for people with cancer and central venous catheters. Cochrane Database Syst Rev (10):CD006468

    Google Scholar 

Further Reading

  • Jacqz-Agrain E, Choonara I (eds) (2006) Paediatric clinical pharmacology. Fontis Media/Taylor & Francis, Lausanne/New York

    Google Scholar 

  • Mulberg AE, Silber SA, van den Anker JN (eds) (2009) Paediatric drug development, concepts and applications. Wiley-Blackwell, Hoboken

    Google Scholar 

  • Rose K, van den Anker JN (eds) (2010) Guide to paediatric drug development and clinical research. Karger, Basel

    Google Scholar 

  • Yaffe SJ, Aranda JV (eds) (2005) Neonatal and pediatric pharmacology, therapeutic principles in practice. Lippincott Williams & Wilkins, Philadelphia

    Google Scholar 

Download references

Disclaimer

The views expressed in this chapter are the personal views of the author and may not be understood or quoted as being made on behalf of or reflecting the position of the European Medicines Agency or one of its committees or working parties.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Christoph Male .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Male, C. (2016). Special Situations III: Medicines for Children. In: Müller, M. (eds) Clinical Pharmacology: Current Topics and Case Studies. Springer, Cham. https://doi.org/10.1007/978-3-319-27347-1_23

Download citation

Publish with us

Policies and ethics